Abstract
The chemotherapeutic options have increased dramatically in patients with gastrointestinal cancer and have led to an improved outcome. With this, an in-depth understanding of the side effects of chemotherapy is becoming increasingly important in order to minimize the negative impact of the use of these agents. Chemotherapeutic agents have a long list of potential side effects. In this chapter, we focus specifically on some of the more common and/or more relevant and challenging side effects related to frequently used agents in gastrointestinal cancer. The fluoropyrimidines may cause cardiac toxicity, most frequently angina-like chest pain. The knowledge of the catabolism of fluorouracil has led to the possibility of testing for dihydropyrimidine dehydrogenase (DPD) in order to avoid serious fluorouracil-related toxicity in patients with DPD deficiency. Oxaliplatin-induced neurotoxicity is probably the most important clinical problem associated with the administration of oxaliplatin. With the increasing use of oxaliplatin, hypersensitivity reactions are more frequently reported and become challenging in clinical practice. The introduction of the targeted agents in colorectal cancer led also to specific problems: the anti-VEGF-related side effects, of which gastrointestinal perforation, although relatively rare, is very relevant for the patient, and the anti-EGFR-related side effects, including skin rash, hypomagnesemia, and allergic reactions, are common. Understanding the underlying causes, mechanisms, risk factors, and developing treatment guidelines has made these side effects often more acceptable for many patients. However, the side-effect profile always has to be balanced against the activity and benefit of the anticancer agents.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27(1):23–44.
Cassidy J, Saltz L, Twelves C, Van Cutsem E, Hoff P, Kang Y, et al. Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Ann Oncol. 2011;22(12):2604–9. Epub 2011 Mar 17.
Becker K, Erckenbrecht JF, Häussinger D, Frieling T. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs. 1999;57(4):475–84.
Ang C, Kornbluth M, Thirlwell MP, Rajan RD. Capecitabine-induced cardiotoxicity: case report and review of the literature. Curr Oncol. 2010;17(1):59–63.
Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008;134(1):75–82. Epub 2007 Jul 17.
Burger AJ, Mannino S. 5-Fluorouracil-induced coronary vasospasm. Am Heart J. 1987;114(2):433–6.
Van Cutsem E, Hoff PM, Blum JL, Abt M, Osterwalder B. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol. 2002;13(3):484–5.
Van Cutsem E. Raltitrexed (Tomudex). Expert Opin Investig Drugs. 1998;7(5):823–34.
Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C. Routine Âdihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin Colorectal Cancer. 2010;9(4):224–8.
Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer. 2007;43(6):1011–6. Epub 2007 Mar 12.
Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renée N, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol. 1994;12(11):2248–53.
Amstutz U, Froehlich TK, Largiadèr CR. Dihydropyrimidine Âdehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics. 2011;12(9):1321–36.
Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. High prevalence of the IVS14  +  1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics. 2002;12(7):555–8.
Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol. 2008;26(13):2131–8. Epub 2008 Feb 25.
Giorgio E, Caroti C, Mattioli F, Uliana V, Parodi MI, D’Amico M, et al. Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation. Cancer Chemother Pharmacol. 2011;68(5):1355–61. Epub 2011 Aug 11.
Yang CG, Ciccolini J, Blesius A, Dahan L, Bagarry-Liegey D, Brunet C, et al. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemother Pharmacol. 2011;67(1):49–56. Epub 2010 Mar 5.
Weickhardt A, Wells K, Messersmith W. Oxaliplatin-induced neuropathy in colorectal cancer. J Oncol. 2011;2011:201593. Epub 2011 Dec 12.
Hoff PM, Saad ED, Costa F, Coutinho AK, Caponero R, Prolla G, et al. Literature review and practical aspects on the management of oxaliplatin-associated toxicity. Clin Colorectal Cancer. 2012;11(2):93–100. Epub 2011 Dec 6.
André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–47.
Gamelin L, Capitain O, Morel A, Dumont A, Traore S, le Anne B, et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res. 2007;13(21):6359–68.
Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol. 2001;85(5):2293–7.
Won HH, Lee J, Park JO, Park YS, Lim HY, Kang WK, et al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer. 2012;118(11):2828–36. doi:10.1002/cncr.26614. Epub 2011 Oct 21.
Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol. 2011;12(12):1151–61. Epub 2011 Jun 28.
Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer – a GERCOR study. J Clin Oncol. 2006;24(3):394–400.
DÃaz-Rubio E, Gómez-España A, Massutà B, Sastre J, Abad A, Valladares M, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The Phase III MACRO TTD Study. Oncologist. 2012;17(1):15–25. Epub 2012 Jan 10.
Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol. 2011;29(4):421–7. Epub 2010 Dec 28.
Park SB, Goldstein D, Lin CS, Krishnan AV, Friedlander ML, Kiernan MC, et al. Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment? J Clin Oncol. 2011;29(18):e553–4; author reply e555-6. Epub 2011 May 23.
Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2012;23(1):200–5. Epub 2011 Mar 22.
Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs. 2010;2010. pii: 207084. Epub 2010 Sep 20.
Kim BH, Bradley T, Tai J, Budman DR. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology. 2009;76(4):231–8. Epub 2009 Feb 25.
Siu SW, Chan WL, Liu KY, Choy TS, Leung TW, Au KH. Re-challenging patients with oxaliplatin allergy: the successful use of a standardised Âpre-medication protocol in a single institute. Clin Oncol (R Coll Radiol). 2011;23(8):558–9. doi:10.1016/j.clon.2011.04.005. Epub 2011 Apr 23.
Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10(6):417–27.
Jenab-Wolcott J, Giantonio BJ. Antiangiogenic therapy in colorectal cancer: where are we 5 years later? Clin Colorectal Cancer. 2010;9 Suppl 1:S7–15.
de Gramont A, de Gramont A, Chibaudel B, Larsen AK, Tournigand C, André T, GERCOR French Oncology Research Group. The evolution of adjuvant therapy in the treatment of early-stage colon cancer. Clin Colorectal Cancer. 2011;10(4):218–26.
Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009;10(6):559–68.
Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol. 2007;14(6):1860–9. Epub 2007 Mar 14.
Walraven M, Witteveen PO, Lolkema MP, van Hillegersberg R, Voest EE, Verheul HM. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis. 2011;14(2):135–41. Epub 2010 Dec 29.
You B, Chen EX. Anti-EGFR Monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab. J Clin Pharmacol. 2012; 52:128–55. [Epub 2011 Mar 22].
Prenen H, Tejpar S, Van Cutsem E. New strategies for treatment of KRAS mutant metastatic colorectal cancer. Clin Cancer Res. 2010;16(11):2921–6. Epub 2010 May 11.
Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16(9):1425–33. Epub 2005 Jul 12.
Segaert S, Chiritescu G, Lemmens L, Dumon K, Van Cutsem E, Tejpar S. Skin toxicities of targeted therapies. Eur J Cancer. 2009;45 Suppl 1:295–308.
Green MR, Couchman JR. Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition. J Invest Dermatol. 1985;85(3):239–45.
Giovannini M, Gregorc V, Belli C, Roca E, Lazzari C, Viganò MG, et al. Clinical significance of skin toxicity due to EGFR-targeted therapies. J Oncol. 2009;2009:849051. Epub 2009 Jun 22.
US National Library of Medicine. ClinicalTrials.gov [online]. http://clinicaltrials.gov/ct2/show/study/NCT01251536 Accessed on sep 14, 2012.
Costa A, Tejpar S, Prenen H, Van Cutsem E. Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents. Target Oncol. 2011;6(4):227–33. doi:10.1007/s11523-011-0200-y. Epub 2011 Nov 24.
Tejpar S, Piessevaux H, Claes K, Piront P, Hoenderop JG, Verslype C, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol. 2007;8(5):387–94.
Groenestege WM, Thébault S, van der Wijst J, van den Berg D, Janssen R, Tejpar S, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest. 2007;117(8):2260–7.
Fakih MG, Wilding G, Lombardo J. Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer. 2006;6(2):152–6.
Fakih M. Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia. Oncology (Williston Park). 2008;22(1):74–6.
Saif MW, Peccerillo J, Potter V. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. Cancer Chemother Pharmacol. 2009;63(6):1017–22. Epub 2008 Sep 10.
George Jr TJ, Laplant KD, Walden EO, Davis AB, Riggs CE, Close JL, et al. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment. J Support Oncol. 2010;8(2):72–7.
Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358(11):1109–17.
Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12(5):601–9.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag London
About this chapter
Cite this chapter
Bogaert, J., Cuyle, PJ., Van Cutsem, E. (2013). Gastrointestinal Cancer: Selection of Clinically Relevant Drug-Induced Toxicities Encountered in Gastrointestinal Cancer Treatment. In: Dicato, M. (eds) Side Effects of Medical Cancer Therapy. Springer, London. https://doi.org/10.1007/978-0-85729-787-7_4
Download citation
DOI: https://doi.org/10.1007/978-0-85729-787-7_4
Published:
Publisher Name: Springer, London
Print ISBN: 978-0-85729-786-0
Online ISBN: 978-0-85729-787-7
eBook Packages: MedicineMedicine (R0)